The recommended 250 mg BID dosing regimen was the maximum tolerated dose for XALKORI determined in a Phase 1 dose-escalation study in patients with advanced solid tumors. Treatment of overdose with XALKORI should consist of symptomatic treatment and other supportive measures. There is no antidote for XALKORI.
For management of a suspected drug overdose, contact your regional Poison Control Centre.